Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation

Ikoma-Colturato, Maura R. V; Beltrame, Miriam P; Furtado, Felipe M; Pimenta, Glicinia; Costa, Elaine Sobral da; Azambuja, Ana Paula; Malvezzi, Mariester; Yamamoto, Mihoko.
Hematol., Transfus. Cell Ther. (Impr.) ; 43(3): 332-340, July-Sept. 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1346264

Documentos relacionados

  1. Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
  2. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
  3. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
  4. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
  5. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
  6. Has MRD graduated from its adolescence in ALL?
  7. Old rivals become new friends.
  8. [State-of-the-art therapy for adult Philadelphia chromosome-negative acute lymphoblastic leukemia].
  9. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
  10. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.